Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Secondary Resistance”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT06801236
What this trial is testing

Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)
Acerand Therapeutics (Hong Kong) Limited 88
Large-scale testing (Phase 3)Study completedNCT00005863
What this trial is testing

Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia

Who this might be right for
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
Medical Research Council
Not applicableLooking for participantsNCT04793737
What this trial is testing

Precision Radiation of Immune Checkpoint Therapy Resistant Melanoma Metastases

Who this might be right for
Metastatic Melanoma
Karolinska University Hospital 27
Not applicableActive Not RecruitingNCT06733337
What this trial is testing

Learn About the Safety of TALZENNA in People With Prostate Cancer.

Who this might be right for
Prostate Cancer
Pfizer 1
Early research (Phase 1)Looking for participantsNCT06062745
What this trial is testing

Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT

Who this might be right for
Advanced Prostate CancerMetastatic Prostate CancerMetastatic Prostate Neuroendocrine Carcinoma
Brigham and Women's Hospital 30
Very early researchStudy completedNCT02113657
What this trial is testing

T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
M.D. Anderson Cancer Center 30
Not applicableTemporarily Not AvailableNCT06033001
What this trial is testing

Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
Castration-Resistant Prostatic Cancer
Lantheus Medical Imaging
Testing effectiveness (Phase 2)Study completedNCT01323400
What this trial is testing

Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST)

Who this might be right for
GIST
Centre Leon Berard 81
Testing effectiveness (Phase 2)Study completedNCT03489629
What this trial is testing

STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)

Who this might be right for
Cystic Fibrosis
University of North Carolina, Chapel Hill 49
Testing effectiveness (Phase 2)UnknownNCT04116775
What this trial is testing

Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.

Who this might be right for
Prostate CancerProstate Cancer Metastatic
Julie Graff, MD 32
Testing effectiveness (Phase 2)Ended earlyNCT02508077
What this trial is testing

FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer

Who this might be right for
Recurrent Colorectal CarcinomaStage IVA Colorectal CancerStage IVB Colorectal Cancer
City of Hope Medical Center 1
Not applicableStudy completedNCT04962919
What this trial is testing

Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Latin American Cooperative Oncology Group 584
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05479045
What this trial is testing

A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients

Who this might be right for
Ovarian Cancer Stage IVOvarian Cancer Stage IIIOvarian Cancer Stage 3
Georgetown University 24
Testing effectiveness (Phase 2)Ended earlyNCT02607228
What this trial is testing

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer

Who this might be right for
Metastatic Castrate-Resistant Prostate Cancer
Gilead Sciences 31
Early research (Phase 1)Ended earlyNCT05047536
What this trial is testing

KZR-261 in Subjects With Advanced Solid Malignancies

Who this might be right for
Advanced/Metastatic Solid Tumor
Kezar Life Sciences, Inc. 61
Early research (Phase 1)Ended earlyNCT06264921
What this trial is testing

A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors

Who this might be right for
Solid TumorSolid Tumor, AdultAdvanced Solid Tumor+26 more
NiKang Therapeutics, Inc. 23
Testing effectiveness (Phase 2)Looking for participantsNCT06084338
What this trial is testing

Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc

Who this might be right for
Prostate Cancer
VA Office of Research and Development 60
Early research (Phase 1)Not Yet RecruitingNCT07244393
What this trial is testing

Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Cellbion Co., Ltd. 30
Testing effectiveness (Phase 2)Looking for participantsNCT04363164
What this trial is testing

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

Who this might be right for
Castration Resistant Metastatic Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 150
Testing effectiveness (Phase 2)Ended earlyNCT02758132
What this trial is testing

Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases

Who this might be right for
Prostate Cancer
University of Hawaii 1
Next Page